Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
En este video de discusión, el Dr. Narjust Duma habla con los Dres. Idalid "Ivy" Franco (Programa de Oncología Radioterápica de Harvard), Ana Velázquez Manana (Centro Integral de Cáncer Familiar Helen Diller de UCSF) y Luis Raez (Jefe de Hematología / Oncología y Director Médico - Memorial Cancer Institute).
Los médicos discuten la epidemiología y la cantidad actual de casos de COVID-19 en Latinx en los Estados Unidos y América Latina, y Covid y el cáncer en los latinos.
*****
In this video discussion, Dr. Narjust Duma speaks with Drs. Idalid "Ivy" Franco (Harvard Radiation Oncology Program), Ana Velazquez Manana (UCSF Helen Diller Family Comprehensive Cancer Center) and Luis Raez (Chief Hematology/Oncology and Medical Director - Memorial Cancer Institute).
The doctors discuss epidemiology and the current number of cases of COVID-19 in Latinx in the US and Latin America, and Covid and cancer in Latinos.
To join the conversation, visit https://cancergrace.org/forum.
Para unirse a la conversación, visite https://cancergrace.org/forum.
Please feel free to offer comments and raise questions in our
discussion forums.
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)
There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...
Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.
The...
Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...
Hi Stan! So good to hear from you. I'm sorry for the late response. I too have been out of town with family and missed your post, probably because I was...
It is so good to hear from you! And I am so happy to hear that your holidays have been good and that you are doing well. It sounds like your...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components: